-+ 0.00%
-+ 0.00%
-+ 0.00%

Polaryx Therapeutics targets Q4 2026 start for SOTERIA Phase 2 PLX-200 basket trial

PUBT·08/25/2026 12:31:39
Listen to the news
Polaryx Therapeutics targets Q4 2026 start for SOTERIA Phase 2 PLX-200 basket trial
  • Polaryx Therapeutics outlined plans to launch its SOTERIA Phase 2 basket trial of PLX-200 in Q4 2026.
  • No clinical results were presented; an interim readout is planned using 52-week maintenance data.
  • Study aims to assess safety, drug exposure, tolerability, and signs of clinical activity in pediatric lysosomal storage disorders.
  • FDA cleared the trial to proceed; PLX-200 received Fast Track Designation across the four planned indications.
  • USD 10 million financing was completed to fund trial initiation and near-term clinical milestones.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608250830PRIMZONEFULLFEED9815444) on August 25, 2026, and is solely responsible for the information contained therein.